Dipyridamole interactions

Drug/Lab test interactions Over the course of 24 months, patients treated with dipyridamole and aspirin combination therapy showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13 X 10 /mm2. 

CPF Borges, S Honda, H Imasato, P Berci, M Tabak. Synthesis, characterization and interactions with ionic micelles of tetraacetylated dipyridamole. Spectrochim Acta A 51 2575-2584, 1995. 

Grem, JL, Mulcahy T, Miller EM, et al. Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line. Biochem Pharmacol 1989 38 51-59. 

Dipyridamole is a vasodilator and interferes with platelet function via intracellular cyclic AMR Adenosine interacts with the adenosine receptors to cause... 

Therapy, in the short term, is with intravenous unfractionated or subcutaneous low molecular weight heparin. Aspirin, given in low doses between 50 and 100 mg per day, is sufficient to diminish platelet-vessel interaction. Alternatives include 100-200 mg of sulphinpyrazone once or twice a day or dipyridamole where 100 mg four times a day can be used on its own or between 25 and 75 mg combined with aspirin three times a day. More recently thiopy-ridines, as a class, has been shown to have equivalence at 250 mg twice a day. In hyperhomocysteinaemia the risk is reduced by 5 mg of folate and 100 mg of vitamin Bg daily, with addition of oral vitamin Bi2 of less clearly defined benefit. The effect of this intervention requires re-assay at 3-monthly intervals, following standard methionine challenge, to ensure that suitable suppression has been achieved in the plasma amino acid level (Table 5). 

Drug interactions Caution is called for when administering tenecteplase with drugs that affect platelet function such as aspirin, dipyridamole, clopidogrel, and glycoprotein Ilb/IIIa inhibitors. Administration of tenecteplase before, during, or after any of these drugs may increase the risk of... 

Several papers proposing multiple recognition sites for Pgp have been presented in the past. In this work, the pharmacophoric analysis of the dataset shows that the requirements to interact with Pgp are the same for all 129 compounds. Since in our database we have not included known R-site binders and anthracydines, we cannot say definitively that the pharmacophore found represents one of the binding sites that have been described in the literature. Two of the molecules present in the database, verapamil and dipyridamole, are known to bind in the H-site described by Shapiro and Ling [10]. We also cannot definitely state that the pharmacophore defines any functional site within the transporter. Further work, to try to define the location of the corresponding amino acids in a protein homology model, is in progress. 

El-Camel, S, Wollert, U, Muller, WE, Optical studies on the specific interaction dipyridamole with alphal-acid glycoprotein (orosomucoid)., J. Pharm. Pharmacol, 1981,34 152-157. 

Weiss HI IhriOo VT, Vide WJ, Baumgartner HR Effect of aspirin and dipyridamole on die interaction of human platelets with sub-endothelium studies using dtrated and native blood. Huomb Haemost 45 136-141,1981. 

Watt AH, Bernard MS, Webster J, Passani SL, Stephens MR, Routledge PA. Intravenous adenosine in the treatment of supraventricular tachycardia a dose-ranging study and interaction with dipyridamole. Br J Chn Pharmacol 1986 21(2) 227-30. 

Drug interactions Methylxanthines e.g., theophylline) and dipyridamole are adenosine antagonists. 

---